Thanksgiving day might have been full of NFL days, but there is still more football action prior to the weekend.
On Friday, there will be 16 FBS games to kick off rivalry weekend, along with a few ranked matchups.
No. 21 San Diego State kicks off the slate at noon with a tough matchup against Boise State. No. 16 Iowa will play its final Big Ten game of the season when it travels to Lincoln, Nebraska, to take on the Cornhuskers in a battle for the Heroes Trophy.
Plenty of eyes will be on No. 4 Cincinnati as it looks to strengthen its College Football Playoff candidacy in its final test before the American Athletic Conference championship game in a matchup against Eastern Carolina. The Utes will also play their final regular-season game, hosting Colorado, before the Pac-12 championship on Dec. 3.
The night slot will feature a pair of rivalry clashes with UNC traveling to Raleigh to play No. 20 NC State, while the latest chapter of the Apple Cup will take place in Seattle with Washington hosting Washington State.
Sporting News breaks down how to watch those games and more in Week 13. Here’s everything you need to know.
MORE: College football picks, predictions against the spread for every Week 13 top 25 game
How to watch, live stream college football games
There will be a full slate of games on national television running from noon through 8 p.m. ET on Friday. The games will appear on CBS, Fox, FS1, CBS Sports Network, ESPN, ESPNU, ESPN+ and ABC. Live streaming options include the ESPN app, Fox.com, ESPN+, Paramount+ and fuboTV, which offers a 7-day free trial.
The Centers for Disease Control and Prevention issued a health advisory Wednesday that cases of influenza have been rising among young adults in recent weeks.
While flu cases are still low nationally, more than 90 percent are among children and young adults ages 5 to 24, according to the CDC.
Most cases are of the H3N2 lineage — a strain that health experts say is particularly troublesome, as it tends to mutate faster than other variants of influenza. The last time H3N2 was the dominant strain was during the 2017-18 flu season, when the U.S. had 710,000 flu-related hospitalizations and 52,000 flu-related deaths, the most since the 2009 H1N1 flu pandemic.
A CDC map shows influenza rates.CDC
The CDC has been investigating a flu outbreak at the University of Michigan, where hundreds of students have tested positive. Flu outbreaks have been reported at other college campuses in the past month.
Experts are concerned that college students and other young people who may have been exposed to flu could spread it around the country as they travel home for the holidays.
“This is the time of the year when many people are going to be gathering together for the holidays for either Thanksgiving, Christmas or New Year’s, and there’s just the potential to amplify it,” said Dr. Isaac Bogoch, an infectious disease specialist at the University of Toronto.
He said people, especially those most at risk for severe disease, should get vaccinated, because the virus doesn’t stay within a particular age group for long.
“It’s coming. It’s not quite clear how large a flu season we’re going to have, but we are going to have a flu season,” he said.
Full coverage of the Covid-19 pandemic
The flu season typically runs from October to as late as May, with activity tending to peak from December to February, according to the CDC.
Influenza experts had previously said they were concerned that the country could be at risk for a severe flu season this year after seasonal flu cases reached an all-time low last year, when large parts of the country were shut down because of the coronavirus pandemic.
Experts urge people to get both Covid and flu vaccinations, saying an increase in flu infections this winter could put more burden on the country’s health care system, which is already dealing with a surge in coronavirus cases.
Download the NBC News app for full coverage of the Covid-19 pandemic
As part of the health advisory, the CDC recommended that people with flulike symptoms be tested for both influenza and Covid.
Go Fashion IPO allotment status: Finalisation of share allotment for Go Fashion IPO can be announced anytime today. Those who have applied for the public issue worth ₹1,013.61 crore are advised to check their application status either at the BSE website or at the website of official registrar of the IPO. The official registrar of the public issue is KFintech Private Limited. However, ahead of the share allotment announcement, Go Fashion share price has appreciated in the grey market. As per market observers, Go Fashion IPO GMP today is ₹475.
Go Fashion IPO GMP
According to market observers, Go Fashion IPO GMP today is ₹475, which is ₹55 higher from its yesterday’s grey market premium of ₹420 per equity share. Market observers said that ₹475 GMP simply reflects that grey market is expecting Go Fashion share listing at around ₹1165, which is around 65 per cent higher from its price band of ₹655 to ₹690 per share.
Go Fashion IPO allotment links
As mentioned above, Go Fashion IPO bidders can check their application status online by logging in at BSE website or at KFintech website. For more convenience, they can login at direct BSE link — bseindia.com/investors/appli_check.aspx or at direct KFintech link — kprism.kfintech.com/ipostatus and check share allotment status.
How to check Go Fashion IPO allotment status on KFintech
After the announcement of share allotment, one can check one’s application status online by logging in at above-mentioned direct KFintech link and follow step by step given below:
1] Login at the direct KFintech link — kprism.kfintech.com/ipostatus/;
2] Select Go Fashion IPO;
3] Select either of Application Number or DPID/Client ID or PAN (Let’s take application number);
4] Enter Go Fashion IPO application number;
5] Fill Captcha; and
6] Click at ‘Submit’ button.
Your Go Fashion IPO allotment status will become available on the computer monitor or on the Smartphone screen.
How to check Go Fashion IPO allotment status on BSE
For Go Fashion IPO allotment status check online at BSE, one needs to login at above-mentioned direct link and follow step by step given below:
1] Login at the direct link to BSE website — bseindia.com/investors/appli_check.aspx;
2] Select Go Fashion IPO;
3] Enter your Go Fashion IPO application number;
4] Enter your PAN details;
5] Click at ‘I’m not a robot’; and
6] Click at ‘Submit’ button.
Your Go Fashion IPO allotment status will become available on the computer monitor or on the Smartphone screen.
Subscribe to Mint Newsletters
* Enter a valid email
* Thank you for subscribing to our newsletter.
Never miss a story! Stay connected and informed with Mint.
Download
our App Now!!
The U.S. is home to the three richest families in the world.
The Walton, Mars and Koch families have topped the list of wealthiest clans in the world, according to a September report from Bloomberg.
The families have remained in their positions as the richest in the U.S. and in the world for several years. That’s true even for the Waltons, who have given away millions of dollars during the last year, Bloomberg reported.
JESSICA SIMPSON SPEAKS OUT AFTER RECLAIMING ‘100{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} OWNERSHIP’ OF HER BILLION-DOLLAR BUSINESS
Though the descendants of Walmart founder Sam Walton are the richest family in the world, their wealth, as reported by Bloomberg, doesn’t quite reach the wealth of the richest man in the world, Elon Musk, who is currently worth $290.3 billion, according to the Forbes Real-Time Billionaires List.
The Waltons’ wealth does surpass the wealth of Jeff Bezos, who is currently worth $205.4 billion, according to Forbes. However, the Mars and Koch families have not reached Bezos’ wealth, according to Bloomberg’s September report.
SUBS AND SUCCESS: HOW JIMMY JOHN’S FOUNDER PURSUED HAPPINESS IN THE ART OF SANDWICH-MAKING
Read on to learn more about the three wealthiest families in the world, according to Bloomberg.
The Walton Family
Members of the Walton family are introduced to the audience during the annual shareholders meeting event on June 1, 2018 in Fayetteville, Arkansas. (L-R) Jim Walton, Alice Walton, Jim’s wife Lynne McNabb Walton, Rob Walton’s wife Melani Lowman Walton
Company: Walmart
Wealth: $238.2 billion
Number of generations: Three
Location: Bentonville, Arkansas
Sam Walton opened the first Walmart in Bentonville, Arkansas, in 1962, according to the company’s website. Now, Walmart is the largest retailer in the world.
Mars heiress Jacqueline B. Mars in 2016. (Ron Sachs – Pool via Getty Images)
Company: Mars, Inc.
Wealth: $141.9 billion
Number of generations: Five
Location: McLean, Virginia
Candy company Mars was founded by Frank Mars more than 100 years ago. Despite the well-known candies from Mars – such as Snickers, M&Ms, Twix and Dove – FOX Business previously reported that more than half the company’s revenue comes from pet-care products.
CLICK HERE TO READ MORE ON FOX BUSINESS
The Koch Family
Charles Koch is pictured in 2015. (Photo by Patrick T. Fallon for The Washington Post via Getty Images)
Company: Koch Industries
Wealth: $124.4 billion
Number of generations: Three
Location: Wichita, Kansas
FOX Business previously reported that the wealth of the Koch family began with Fred Koch’s oil firm and was split between his four sons before two sons left in the 1980s. Charles and David Koch were the two sons who stayed, and today, Charles Koch serves as the chairman of the board and CEO. David Koch, who also maintained a position of leadership until 2018, died in August 2019.
Despite dealerships’ tight inventory and automakers being forced to temporarily remove features from new models because of chip shortages, lessees feel their next vehicle will be newer and more advanced than their existing models, according to a survey. The consumers also expected to pay the same amount or less than their current bill.
The Oct. 15 Pollfish study of 1,000 leaseholders found 82 percent of lessees were concerned supply issues could affect the availability of their next model, according to CoPilot, the car-shopping assistance company that commissioned the study.
But 66 percent felt their next model would be an upgrade in terms of features, and 92 percent thought their next lease or purchase would be newer, CoPilot’s survey found. Fifty-six percent of customers thought it would cost them the same amount or less.
Even customers in the crunch time of three months or less left on their leases are confident they’ll move to newer and better vehicles for the same or reduced cost. Ninety percent felt they’d get a newer model, and 57 percent expected to get something with better features. Sixty-six percent thought this new purchase or lease would be the same or less than what they were paying now.
“As millions of consumers come off-lease this year, they should be prepared for the fact that the car they want may not be available,” CoPilot CEO and co-founder Pat Ryan said in a statement this month. “Due to the global chip shortage, a number of major automakers have announced that they need to suspend tech features like driver assistance and monitoring systems and blind spot monitoring. As a result, consumers looking to lease their next car may be facing the reality that their next vehicle may not have all the bells and whistles they’re hoping for — or even safety add-ons that they’ve come to view as standard.”
Customers are beginning to understand the reality of the industry, though. Ryan told Automotive News that four months ago, customers would have been completely clueless. Now, they’re aware of the shortages, but “they’re not sure it’s gonna impact them.” It’s not until a consumer enters the market that they recognize the challenge, he said.
Vehicles are still being made available for lease, though they’re not being subvented to the levels in the past, Ryan said. Customers might also need to settle for leasing a vehicle that doesn’t precisely meet their desired configuration, or they might sign up for a lease that would begin when a vehicle becomes available months later.
CoPilot has been advising lessees who don’t need a vehicle immediately to “buy out and keep an eye out,” according to Ryan: Purchase one’s current lease at the residual price and wait for better market conditions.
He said automakers also are less willing than in the past to extend leases for customers whose desired vehicle isn’t yet available.
“That’s kind of come and gone by now,” Ryan said.
As for the customers shopping for leases today, Ryan said they should still receive comparable residuals. Even though a 1- to 3-year old car now sells for 92 percent of sticker price instead of the usual 70 percent, lessors aren’t making dramatic changes to lessee buyout prices in response to current market conditions, he said.
“Nobody believes that’ll be true in three years,” he said.
Ryan also said the difficult lease results recently reported by some mainstream automakers might not indicate what’s happening among luxury brands, which rely more heavily on leasing for their business model. A mass-market volume brand will lease to help boost the car sales they’d prefer to focus on, he said. A premium brand treats leasing as a goal unto itself, he said.
Share on PinterestCould fasting-mimicking diets help treat cancer? 10’000 Hours/Getty Images
A recent study investigated the safety, tolerability, and metabolic- and immune-related effects of fasting-mimicking diets (FMDs) in participants with cancer.
The results demonstrated that metabolic and immune changes were consistent with improved cancer outcomes, but they did not prove effectiveness.
More research is necessary to determine whether FMD-induced metabolic and immune effects improve the efficacy of standard cancer treatment and reduce mortality.
Changes in the types and amount of food a person eats can have positive effects on health and aging. Some evidence suggests that prolonged fasting may activate protective cellular mechanisms.
Scientists believe that these effects are partially due to temporary reductions in glucose, insulin, and insulin-like growth factor 1 (IGF-1). IGF-1 is a hormone that regulates growth, controls skeletal muscle metabolism, and rebuilds muscles in the human body.
As IGF-1 regulates cell growth and division, cell death, and cell survival, it may also promote the growth of cancerous tumors.
Preliminary studies with periodic cycles of prolonged fasting demonstrated antitumor effects, enhanced response to anticancer therapy, and protection of healthy cells from chemotherapy-induced damage.
However, complying with prolonged fasting and severe calorie restrictions may be challenging and have safety issues.
With this in mind, scientists have developed a “fasting-mimicking diet (FMD),” which is low in calories, sugars, and protein. The aim is to achieve effects similar to those that animal studies have shown to occur through fasting while preventing nutrient deficiencies.
The latest study is the first trial to investigate FMD in people with cancer.
Lead author Dr. Claudio Vernieri, Ph.D., a medical oncologist and director of the Metabolic Reprogramming in Solid Tumors program at the FIRC Institute of Molecular Oncology (IFOM), explained to Medical News Today:
“Based on […] striking preclinical data, we decided to test if a severely calorie-restricted dietary regimen, which we specifically designed for use in oncology, could be well-tolerated by cancer patients and if [it] was sufficiently potent to modulate relevant metabolic and immunologic parameters.”
The researchers gave 101 participants with cancer an identical FMD for 5 days. The participants consumed up to 600 calories on day 1 and up to 300 calories on days 2–5. They followed this period of caloric restriction with 16–23 days of refeeding to regain the lost weight. The individuals then repeated these regimens every 3 or 4 weeks for up to eight cycles.
On average, participants went through four of these FMD cycles.
The study included people who had different types of cancer in various stages and were taking different anticancer treatments. It excluded individuals who were underweight or had a high risk of malnourishment.
In the 99 participants whom the team assessed, FMD reduced serum glucose levels by 18.6{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809}, serum insulin by 50.7{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809}, and serum IGF-1 by 30.3{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809}. These results were independent of the type of cancer, anticancer treatment, and stage of cancer.
The researchers assessed insulin levels because evidence suggests that this hormone stimulates cancer cell growth. Similarly, some evidence suggests that higher serum glucose levels also promote cancer progression.
After 5 days, the blood samples of 38 FMD-treated participants showed a significant decline in specific white blood cells called myeloid cells that are associated with immune suppression. They also had increased numbers of cytotoxic T cells, immune cells that can kill cancer cells. Both of these changes were independent of anticancer treatment.
The researchers then focused on a subset of 13 participants who had advanced triple-negative breast cancer and were receiving first-line cytotoxic chemotherapy (ChT). They compared immune changes between those receiving both ChT and FMD and 13 participants receiving ChT alone.
In the dual treatment group, the scientists measured similar immune effects: decreases in immunosuppressive myeloid cells and increases in activated CD8+ T cells, which are a type of cytotoxic T cell. In the group that took ChT alone, these immune changes were not present.
The study also reported an interim analysis of immune responses to FMD in 22 people with early stage breast cancer awaiting surgery. These participants started FMD 12–15 days before their surgery.
In these individuals, FMD produced similar metabolic changes, namely decreases in blood glucose, insulin, and IGF-1. The researchers also observed significant immune changes, which indicated the activation of an anticancer environment at the tumor level.
Dr. Vernieri told MNT, “The most relevant finding of the study is that our fasting-mimicking diet regimen boosts the immune system by activating specific immune cells that are clearly recognized as crucial in recognizing and killing cancer cells.”
One of the study’s strengths is that FMD safely produced the desired anticancer metabolic and immunologic changes across all study participants, regardless of the type of cancer, cancer severity, and anticancer treatment.
“The main limitation of our study,” Dr. Vernieri explained, “is the fact that the heterogeneity of enrolled patients does not allow [us] to conclude about the antitumor efficacy of the fasting-mimicking diet.”
MNT also spoke with Dr. Steven Vasilev, who was not involved in the study. Dr. Vasilev is an oncologist and medical director of Integrative Gynecologic Oncology at Providence Saint John’s Health Center in Santa Monica, CA. He is also a professor at Saint John’s Cancer Institute, which is also in Santa Monica.
Speaking about the challenges in interpreting the results, he said:
“You’re […] essentially trying to starve someone for some period of time, which leads to an incredibly complex immunological and metabolic response. Then [you’re] trying to figure out which [factor] is […] the one that’s responsible for returning tumor growth. And the answer is: It’s probably all of them, but you [don’t] know which one is the most essential.”
Dr. Vasilev explained that many cancer patients are already malnourished. For safety and ethical reasons, the current study did not include participants at high risk of malnourishment. This exclusion introduces bias, albeit necessary bias.
He also outlined a number of clinical limitations that need ironing out before doctors could use caloric restriction to treat cancer patients. For instance, he suggested that reducing calorie intake might have a negative effect on wound healing.
However, Dr. Vasilev also reiterated that much more research is necessary before this type of intervention enters the clinic.
Dr. Vernieri spoke with MNT about the next steps, saying, “Additional trials must be conducted in well-selected patient populations to clarify in which clinical contexts fasting-mimicking diet could be combined with standard anticancer therapies to improve their antitumor activity and efficacy.”
“In this perspective,” he continued, “we are conducting the phase 2, randomized trial BREAKFAST to investigate if combining severe calorie restriction with standard preoperative chemotherapy is capable of improving tumor responses in patients with limited-stage triple-negative breast cancer.”
He added, “I would like to highlight that to guarantee the safety of calorie restriction, patients should be managed by multidisciplinary teams with specific expertise in the field of fasting in oncology, and only in the context of clinical trials.”
